Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, and acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix is a trivalent combination vaccine developed by GSK for active immunization against diphtheria, tetanus, and pertussis. It is a non-infectious, sterile vaccine containing diphtheria toxoid, tetanus toxoid, and three purified acellular pertussis antigens: pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (69 kiloDalton outer membrane protein). These antigens are adsorbed onto aluminum hydroxide, which serves as an adjuvant to enhance the immune response. Infanrix is typically administered as a 5-dose series in infants and children from 6 weeks through 6 years of age (prior to the 7th birthday). It is designed to induce protective antibody levels and immune memory without the reactogenicity associated with older whole-cell pertussis vaccines.
- Brand names
- Infanrix
- Other names
- DTaP vaccineDTPa vaccineDiphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
02
Targets
PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on diphtheria, tetanus, and acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, and acellular pertussis vaccine.